Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 17, 2025

Sofinnova closes €650m healthcare fund for early-stage ventures

Sofinnova Partners has closed its latest Sofinnova Capital XI fund, aimed at supporting early-stage healthcare companies in the US and Europe, at €650m ($750m) above its initial target.

The fund draws on the strength of its experienced team. Credit: Sofinnova Partners.